ClinicalTrials.gg
CompletedNCT00206622Updated May 29, 2009

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

A Phase 4 interventional study of Climara PRO (Estradiol / Levonorgestrel transdermal) and Menostar (Estradiol transdermal) in Hot Flashes, sponsored by Bayer. Completed at 45 sites in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2009-05-29.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
425
Allocation
Randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.

Enrollment
8th of 13
425 · median 431
Started
2004
with 2 others
Phase 4
Only one
of the 13
Registered
2nd of 13
by date
Lead sponsor
4 of 13
Bayer

Among the 13 studies testing estradiol in Hot Flashes, this one is the 8th largest by enrollment, is one of 3 that started in 2004, is the only one in phase 4, and was the 2nd registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing estradiol in Hot Flashes as a file.
02

Study summary

To determine the lowest effective dose of estradiol by comparing E2/LNG (2.2mg/0.69mg) and E2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women

Read the detailed description

This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.

03

Conditions studied

  • Hot Flashes

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Menopause
  • Reporting a minimum of 7 moderate to severe hot flushes per day for at least 1 week (7 consecutive days), or a minimum of 50 moderate to severe hot flushes per week for at least 1 week (7 consecutive days)

Exclusion criteria

Exclusion Criteria:

  • Hormonal treatment
  • to estrogen/progestogen therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
425 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: Climara PRO (Estradiol / Levonorgestrel transdermal)

  • Active comparator
    Arm 2

    Drug: Menostar (Estradiol transdermal)

  • Placebo comparator
    Arm 3

    Drug: Placebo transdermal

Interventions

  • DrugClimara PRO (Estradiol / Levonorgestrel transdermal)

    2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch

  • DrugMenostar (Estradiol transdermal)

    Drug pages: Estradiol · Ethinyl Estradiol

    1mg 17 Beta-estradiol transdermal patch

  • DrugPlacebo transdermal

    Placebo

06

What researchers measure

Primary outcomes

  1. Lowest effective dose in decreasing the frequency and severity of hot flushes

Secondary outcomes

  1. Other symptoms related to menopause

07

Study locations

45 sites
  • Huntsville, Alabama 35801, United States
  • Chandler, Arizona 85225, United States
  • Phoenix, Arizona 85031, United States
  • Tucson, Arizona 85712, United States
  • Fair Oaks, California 95628, United States
  • Oakland, California 94612, United States
  • San Diego, California 92103, United States
  • San Diego, California 92108, United States
  • San Diego, California 92123, United States
  • New Britain, Connecticut 06050, United States
  • West Hartford, Connecticut 06117, United States
  • Fort Myers, Florida 33916, United States
  • Gainesville, Florida 32610-0254, United States
  • Jacksonville, Florida 32216, United States
  • Tampa, Florida 33613, United States
  • West Palm Beach, Florida 33409, United States
  • Alpharetta, Georgia 30005, United States
  • Boise, Idaho 83702, United States
  • Idaho Falls, Idaho 83404, United States
  • Champaign, Illinois 61820, United States
  • Chicago, Illinois 60612, United States
  • Peoria, Illinois 61615, United States
  • South Bend, Indiana 46601, United States
  • Lexington, Kentucky 40536, United States
  • New Orleans, Louisiana 70115, United States
  • New Orleans, Louisiana 70118-1034, United States
  • Detroit, Michigan 48201, United States
  • St. Louis, Missouri 63110, United States
  • Lincoln, Nebraska 68510, United States
  • Reno, Nevada 89502, United States
  • New Brunswick, New Jersey 08901, United States
  • Albuquerque, New Mexico 87102, United States
  • Winston-Salem, North Carolina 27103, United States
  • Cincinnati, Ohio 45236, United States
  • Cleveland, Ohio 44122, United States
  • Columbus, Ohio 43213, United States
  • Philadelphia, Pennsylvania 19114, United States
  • Pittsburgh, Pennsylvania 15206, United States
  • Memphis, Tennessee 38120, United States
  • Arlington, Texas 76012, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77030, United States
  • Temple, Texas 76502-1896, United States
  • Salt Lake City, Utah 84124, United States
  • Burlington, Vermont 05401-1420, United States
08

References and documents

Publications

  • Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007 Oct;110(4):771-9. doi: 10.1097/01.AOG.0000284450.51264.31. PubMed 17906008 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 21, 2005
Start
Dec 2004
CompletionActual
Feb 2006
Last update
May 29, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00206622
Lead sponsor
Bayer
First posted
Sep 21, 2005
Start date
Dec 2004
Completion
Feb 2006
Last update
May 29, 2009

Study contacts

Bayer Study Director
study director · Bayer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Ethinyl Estradiol

Start the discussion